VITAMIN D AND OUTCOMES IN PEDIATRIC PATIENTS WITH HIGH-RISK NEUROBLASTOMA (HR-NB). AN UNTAPPED APPROACH IN PEDIATRIC CANCER

被引：0
|
作者：
Izurieta Pacheco, Ana Carolina [1 ]
Gimenez, Ana Sangros [1 ]
Martinez, Esther [1 ]
Perez, Sara [1 ]
Gorostegui, Maite [1 ]
机构：
[1] Hosp San Juan Dios, Pediat Canc Ctr Barcelona, Oncol Dept, Barcelona, Spain
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO069a
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [1] Little Effect of Etoposide on High-risk Neuroblastoma (HR-NB) Patients Survival
    Kiyotani, Chikako
    Shioda, Yoko
    Osumi, Tomoo
    Tomizawa, Daisuke
    Kato, Motohiro
    Terashima, Keita
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S43 - S43
  • [2] PATTERN OF RELAPSE IN HIGH-RISK NEUROBLASTOMA (HR-NB) PATIENTS CONSOLIDATED WITH NAXITAMAB
    Rodriguez, Amalia Varo
    Vallejo, Elena Soques
    Gorostegui, Maite
    Zallo, Laura Andres
    Munoz Perez, Juan Pablo
    Heredia, Alicia Castaneda
    Mora, Jaume
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S231 - S231
  • [3] HIGH RISK NEUROBLASTOMA (HR-NB) WITH MNA AND AGE
    Ladenstein, Ruth
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Ash, Shifra
    Beck-Popovic, Maja
    Balwierz, Walentyna
    Boterberg, Tom
    Chan, Godfrey Chi Fung
    Elliott, Martin
    Kogner, Per
    Lode, Holger
    Laureys, Genevieve
    Luksch, Roberto
    Malis, Josef
    Owens, Cormac
    Papadakis, Vassilios
    Sarnacki, Sabine
    Taschner-Mandl, Sabine
    Schleiermacher, Gudrun
    Canete, Adela
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S89 - S89
  • [4] Naxitamab and GM-CSF for consolidation of high-risk neuroblastoma (HR-NB) patients in complete remission.
    Mora, Jaume
    Castaneda, Alicia
    Perez-Jaume, Sara
    Gorostegui, Maite
    Santa-Maria, Vicente
    Pablo Munoz, Juan
    Varo, Amalia
    Mane, Salvador
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients
    Chang, Hsiu-Hao
    Liu, Yen-Lin
    Lu, Meng-Yao
    Jou, Shiann-Tarng
    Yang, Yung-Li
    Lin, Dong-Tsamn
    Lin, Kai-Hsin
    Tzen, Kai-Yuan
    Yen, Ruoh-Fang
    Lu, Ching-Chu
    Liu, Chia-Ju
    Peng, Steven Shinn-Forng
    Jeng, Yung-Ming
    Huang, Shiu-Feng
    Lee, Hsinyu
    Juan, Hsueh-Fen
    Huang, Min-Chuan
    Liao, Yung-Feng
    Lee, Ya-Ling
    Hsu, Wen-Ming
    ONCOTARGET, 2017, 8 (03) : 4360 - 4372
  • [6] LEARNING OUTCOMES ON NURSING CARE FOR PEDIATRIC PATIENTS WITH HIGH-RISK NEUROBLASTOMA
    Roc, Anne
    Turell, Wendy
    Saggio, Jennifer
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [7] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Mora, Jaume
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
  • [8] Fanconi Anemia (FA) pathway and ATM crosstalk in chemoresistant ALT-positive high-risk neuroblastoma (HR-NB)
    Akter, Jesmin
    Mukae, Kyosuke
    Takenobu, Hisanori
    Haruta, Masayuki
    Ohira, Miki
    Ando, Kiyohiro
    Kamijo, Takehiko
    CANCER SCIENCE, 2025, 116 : 1594 - 1594
  • [9] Retinoic acid (RA) relieves EZH2-mediated epigenetic suppression in high-risk neuroblastoma (HR-NB)
    Banerjee, Deblina
    Liu, Zhihui
    Oh, Doo-Yi
    Cam, Maggie
    Kim, Bong-Hyun
    Thiele, Carol
    CANCER RESEARCH, 2017, 77
  • [10] Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma
    Hill-Kayser, Christine E.
    Tochner, Zelig
    Li, Yimei
    Kurtz, Goldie
    Lustig, Robert A.
    James, Paul
    Balamuth, Naomi
    Womer, Richard
    Mattei, Peter
    Grupp, Stephen
    Mosse, Yael P.
    Maris, John M.
    Bagatell, Rochelle
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (02): : 401 - 408
12345